With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster, Firdapse, for $4.1 billion. Rome-based ...
Rare-disease specialist Catalyst Pharmaceuticals is set to be acquired by healthcare group Angelini Pharma in a $4.1 billion deal. Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s ...
Transition metal phosphides have emerged as versatile hydroprocessing catalysts owing to their unique combination of metallic conductivity, tunable electronic structure and strong resistance to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results